Abstract: Baiyun Mountain armored force Viagra Economy: half dose of the price drop 30% armored “* *” listing: Baiyun Mountain (27.62, -0.39, -1.39%) force “Viagra” economy in October 28th, twenty-first Century economic report reporter from gphl Baiyun Mountain (600332.SH, 00874.HK) was informed by production the company’s first Chinese Viagra – Baiyun Mountain armored (sildenafil citrate, commonly known as “Viagra”) officially listed. It is understood that the final price for MR: bulk terminal retail price of 48 yuan, 10 capsules average retail price of 34.5 yuan / tablets, compared with the original products, the same dose of prices fell 30%. “Future armored to pharmacies, to the hospital for the root, supplemented by other channels, relying on the price advantage of armored anti ED drugs, occupy the three foreign brands of high-end market share.” Gphl Great Southern plate director Wang Wenchu said, the Baiyun Mountain armored gphl proposed goal is to hope to scale 500 million annual sales of 1 billion yuan in three to five years, becoming the first brand of China anti ED drugs. Same dose price dropped by 30%, at present, the domestic sale of anti ED drugs are basically Pfizer, Eli Lilly and Bayer three foreign pharmaceutical companies monopoly, drug prices from 90-136 yuan / granule. Since Mr gphl announced since its price has been approved, is the focus of attention of the parties. Previously, gphl has confirmed that apart from Pfizer Viagra 100mg/ grains, Baiyun Mountain armored units to 50mg/ particle for dose. It is understood that the United States FDA update to Sildenafil Citrate Tablets manual in March this year, the Sildenafil Citrate Tablets for the recommended dose of ED treatment in the specification is 50mg, this is the recommended dose of ED patients in the world, which is the maximum recommended dose of 100 mg. Because Mr and half dose of generics, so the industry generally expects its pricing is halved again in half basis, but eventually the Baiyun Mountain armored pricing only than the original products fell by 30%. According to gphl Baiyun Mountain released the latest price display, retail price for a Mr 48 yuan / box, two capsules 89 yuan / box, three capsules 133 yuan / box, 4 capsules 178 yuan / box, 10 capsules 345 yuan / box. Since the 50mg/ granule was used as a unit of dosage, the dose of the single dose decreased by half and the amount of the single dose decreased by more than 60% compared with that of the original product. This is the “gphl pricing that has a great price advantage”. Wang Wenchu, the Baiyun Mountain armored products, the future will be in the three aspects: one is to force pharmacies, to the hospital for the root, supplemented by other channels, relying on the price advantage of armored anti ED drugs, occupy the three foreign brands of high-end market share; the two is to rely on the exact curative effect of the product, the market share occupied end the polyclonal antibody of ED drugs; three is through the education of doctors and patients to raise public awareness and attention on ED, promoting ED drugs market expansion. But some analysts believe that, in addition to gphl Baiyun Mountain first approved, currently including Jilin Henghe and Changzhou techpool biological, pharmaceutical, Jiangsu Yabang Aipu Dunlop pharmaceutical and other 10 companies have proposed a Generic Viagra declaration, the Baiyun Mountain armored pricing at the same time to the enterprise to leave enough space for development. Create “Viagra” in the economy, according to the survey data of American IMS health company, in 2013 the domestic anti ED drug market, Pfizer Viagra occupy 58.8% of the market share of 27 in the main city, with annual sales of more than 1 billion yuan; while the Lilly and Bayer Cialis Aili respectively accounted for 34.6% and 6.6%. In China, ED is one of the four diseases with the highest incidence of male reproductive system. Statistics show that China’s men over 40 years of age ED incidence of about 46%, about 127 million patients, the market potential of up to 10 billion, but ultimately, Baiyun Mountain can be divided, how much is the key issue. According to Wang Wenchu, the current Baiyun Mountain pharmaceutical factory has domestic DASHENLIN Nepstar, large chain pharmacies signed October 28th distribution of sync in the provinces, is expected to be completed in December 11, the first round of distribution. Baiyun Mountain Jinge gphl is a strategic product, we will from the comprehensive technology, brand and channel three aspects for the whole group of armored force building.” Guangzhou Pharmaceutical Group Deputy General Manager Liu Juyan told reporters. Guangzhou Pharmaceutical Group Chairman Li Chuyuan said earlier, Mr is only one of the company began in the area of anti ED, Baiyun Mountain Viagra products in the future will also develop a series of development of Chinese medicine, including Viagra, grab imitation of other anti ED drugs, ED drug product line. According to the reporter, in the recent past National Day day, Wong Lo Kat [micro-blog] health and Viagra gphl a wholly owned subsidiary of Baiyun Mountain’s father Murad Murad jointly established Wanglaoji biotechnology limited company, plans to use Murad to create the “no theory” technology to open up more markets, the first anti-aging pomegranate juice is currently wildly beating gongs and drums in development. “Wang Laoji had also launched the jelly, mung bean and other cross-border products, but because the market for herbal tea Wang Laoji impression is ingrained, so the market reaction, the future if you want to do Wang Laoji pomegranate juice, how positioning will be a big problem.” A beverage industry insiders told reporters. The first half of this year, Baiyun Mountain Guangzhou Pharmaceutical revenues of 10 billion 20 million yuan, an increase of 10.45%; attributable to shareholders of listed companies net profit of 674 million yuan, an increase of 14.72%, but the pharmaceutical business income has recorded a decline. Among them, the total income of traditional Chinese medicine and chemical drugs about 3 billion 570 million yuan, down about 6%, and gross margin also fell by 1.7 percentage points to 38.8%. Huatai Securities (9.80, 0.33, 3.48%) research report that, due to the larger base of Baiyun Mountain Guangzhou Pharmaceutical Pharmaceutical business, future growth elasticity is limited, but Mr will be listed on the pharmaceutical business this year is expected to bring vitality to the company’s main pharmaceutical industry net profit growth rate is about 10%.